On-demand Webinar

Preclinical Drug-Resistant Tumor Models for Cancer Drug Development

Drug resistance represents a fundamental biological challenge, as cancers evolve under therapeutic pressure through mechanisms such as genetic mutations, activation of alternative survival pathways, and adaptation of the tumor microenvironment, and severely limits treatment options.

In this short webinar, our Head of Cancer Pharmacology Preclinical Jingjing (Jessie) Wang details how resistance modeling is the indispensable research engine that drives the development of more resilient, intelligent, and ultimately successful treatment strategies. Learn about Crown Bioscience’s establishment and validation of series of resistant tumor models, a robust preclinical tool for the next generation therapeutics focusing on drug resistance.

Watch a preview clip:

What You’ll Learn:

The establishment and application of clinical pretreated PDX and PDXO models with detailed treatment histories including ADCs, inhibitors etc. for drug resistant evaluations.
The establishment and characterization of drug induced resistant PDX models for next-generation drug development.
The establishment and characterization of engineered resistant models for drug screening.

About the Presenter:

Jingjing (Jessie) Wang, PhD, Executive Director, Head of Cancer Pharmacology, General Manager of Crown Bioscience (Taicang), Crown Bioscience Inc.

Dr. Wang is a trained cancer biologist specialized research expertise in cancer pharmacology, Immuno-oncology, and Endocrinology. She earned her Ph.D. in Pharmacology from National University of Singapore.

She Joined Crown Bioscience in 2015 and currently serves as the Executive Director of the Cancer Pharmacology Department and the General Manager of the Crown Bioscience (Taicang). In this capacity, Dr. Wang provides comprehensive strategic and operational leadership. She is directly responsible for driving the development of the company's cancer pharmacology research and pre-clinical tumor model platforms and overseeing the general management of the Taicang branch.

A key achievement under her leadership has been the establishment of large cohort of cancer patient-derived xenograft (PDX) model library for preclinical and translational research. Her work has also encompassed the development of critical experimental models including cell line-derived models (CDX), immune-oncology murine models, spontaneous murine tumor models, and humanized mouse models.

Leveraging these advanced platforms, Dr. Wang has collaborated extensively with numerous pharmaceutical companies to support their drug discovery pipelines, preclinical evaluations, and Investigational New Drug (IND) applications, thereby accumulating profound experience in preclinical pharmacology and translational research.